



02-03-05

1614
JFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mohsen Shahinpoor, Parsa
Shahinpoor, & David Soltanpour Art Unit: 1614

Serial No. : 10/064,627 Examiner: Kevin E. Weddington

Filed : July 31, 2002 Docket No.: 2002-4-MO

For : Nitric Oxide (NO) Donor+cGMP-PDE5 Inhibitor As A Topical Drug For
Glaucoma



RESPONSE TO OFFICE ACTION

ATTN: COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

This paper is in response to the office action dated October 26, 2004. Please amend the application, without prejudice, as follows:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: ATTN: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on the 25 day of January, 2005.


Mohsen Shahinpoor, Parsa Shahinpoor, David Soltanpour
Date Signed: January 25, 2005 

Please Amend the claims as follow:

1- (amended) Method for lowering ocular hypertension, comprising administering, to a patient in need thereof, a topical ophthalmic eye drop or ointment containing NO releasing agent Pyrimidine and cGMP-PDE5 inhibitor Sildenafil Citrate.

2- (original) Method according to claim 1, wherein said topical ophthalmic eye drop or ointment is in the form of an aqueous solution or suspension, or in the form a gel, or a cream in a pharmaceutically acceptable ophthalmic vehicle, or in the form of an erodible ocular insert or of a "reservoir" system with a polymer membrane or a gel to be placed in the conjunctival sac.

3- (amended) Methods according to claims 1 and 2, wherein the No releasing agent in said ophthalmic medicament is nitroglycerine.